Journal for ImmunoTherapy of Cancer: 9 (3)

Editorial

Perspectives on COVID-19 and cancer immunotherapy: a review series (9 March, 2021)
Jason D Goldman, Paolo Antonio Ascierto

Case report

Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report (25 March, 2021)
Khashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, Robin Billick, Kevin Pehr, Margaret Redpath, Osama Roshdy, Wilson H Miller

Commentary

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report (25 March, 2021)
Marie-Léa Gauci, Barouyr Baroudjian, Celeste Lebbe, Olivier Roux
Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
(18 March, 2021)
Dimitrios C Ziogas, Helen Gogas
Letter to the editor: Hypoxia kinetics and histology in combined radiotherapy and oxidative phosphorylation inhibition effects on antitumor immunity (11 March, 2021)
Daan F Boreel, Paul N Span, Johan Bussink

Basic tumor immunology

Original research: Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer (24 March, 2021)
Maximilian Kießler, Ioana Plesca, Ulrich Sommer, Rebekka Wehner, Friederike Wilczkowski, Luise Müller, Antje Tunger, Xixi Lai, Anke Rentsch, Kenneth Peuker, Sebastian Zeissig, Adrian M Seifert, Lena Seifert, Jürgen Weitz, Michael Bachmann, Martin Bornhäuser, Daniela Aust, Gustavo Baretton, Marc Schmitz
Original research: Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer (22 March, 2021)
Gaopeng Li, Guoliang Wang, Fenqing Chi, Yuqi Jia, Xi Wang, Quankai Mu, Keru Qin, Xiaoxia Zhu, Jing Pang, Baixue Xu, Guangen Feng, Yuhu Niu, Tao Gong, Hongwei Zhang, Xiushan Dong, Ting Liu, Jinfeng Ma, Zefeng Gao, Kai Tao, Feng Li, Jun Xu, Baofeng Yu
Original research: Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer (22 March, 2021)
Xu Cao, Bolei Li, Jing Chen, Jessica Dang, Siqi Chen, E Gulsen Gunes, Bo Xu, Lei Tian, Sabina Muend, Mustafa Raoof, Christiane Querfeld, Jianhua Yu, Steven T. Rosen, Yingyu Wang, Mingye Feng
Original research: Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells (19 March, 2021)
Maxwell Y Lee, Yvette Robbins, Cem Sievers, Jay Friedman, Houssein Abdul Sater, Paul E Clavijo, Nancy Judd, Edward Tsong, Chris Silvin, Patrick Soon-Shiong, Michelle R Padget, Jeffrey Schlom, James Hodge, Christian Hinrichs, Clint Allen
Original research: Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy (12 March, 2021)
Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Celia Reynders, Thomas Lerho, Diane Bruyere, Alizee Lebeau, Coraline Radermecker, Margot Meunier, Marie-Julie Nokin, Elodie Hendrick, Olivier Peulen, Philippe Delvenne, Michael Herfs
Original research: N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells (10 March, 2021)
Yi Sun, Jun Jing, Huan Xu, Lingfan Xu, Hailiang Hu, Cai Tang, Shengzhuo Liu, Qiang Wei, Ruiqi Duan, Ju Guo, Lu Yang
Original research:
CXCR6 deficiency impairs cancer vaccine efficacy and CD8⁺ resident memory T-cell recruitment in head and neck and lung tumors
(10 March, 2021)
Soumaya Karaki, Charlotte Blanc, Thi Tran, Isabelle Galy-Fauroux, Alice Mougel, Estelle Dransart, Marie Anson, Corinne Tanchot, Lea Paolini, Nadege Gruel, Laure Gibault, Francoise Lepimpec-Barhes, Elizabeth Fabre, Nadine Benhamouda, Cecile Badoual, Diane Damotte, Emmanuel Donnadieu, Sebastian Kobold, Fathia Mami-Chouaib, Rachel Golub, Ludger Johannes, Eric Tartour
Original research: Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3 (10 March, 2021)
Zhengjun Zhou, Pengcheng Wang, Rongqi Sun, Jia Li, Zhiqiang Hu, Haoyang Xin, Chubin Luo, Jian Zhou, Jia Fan, Shaolai Zhou
Original research: Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity (2 March, 2021)
Aiqin Gao, Xia Liu, Wenli Lin, Jingnan Wang, Shuyun Wang, Fusheng Si, Lan Huang, Yangjing Zhao, Yuping Sun, Guangyong Peng

Clinical/translational cancer immunotherapy

Original research: Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer (31 March, 2021)
Jacob Gadwa, Thomas E Bickett, Laurel B Darragh, Michael William Knitz, Shilpa Bhatia, Miles Piper, Benjamin Van Court, Shiv Bhuvane, Diemmy Nguyen, Varuna Nangia, Emily K Kleczko, Raphael A Nemenoff, Sana D Karam
Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy (31 March, 2021)
Justin Ferdinandus, Martin Metzenmacher, Lukas Kessler, Lale Umutlu, Clemens Aigner, Karl-Otto Kambartel, Viktor Grünwald, Wilfried Ernst Erich Eberhardt, Wolfgang Peter Fendler, Ken Herrmann, Martin Faehling, Daniel Christian Christoph
Original research: Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA (31 March, 2021)
Mark Kalinich, William Murphy, Shannon Wongvibulsin, Vartan Pahalyants, Kun-Hsing Yu, Chenyue Lu, Feicheng Wang, Leyre Zubiri, Vivek Naranbhai, Alexander Gusev, Shawn G Kwatra, Kerry L Reynolds, Yevgeniy R Semenov
Original research: Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) (24 March, 2021)
Marijo Bilusic, Sheri McMahon, Ravi A Madan, Fatima Karzai, Yo-Ting Tsai, Renee N Donahue, Claudia Palena, Caroline Jochems, Jennifer L Marté, Charalampos Floudas, Julius Strauss, Jason Redman, Houssein Abdul Sater, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James L Gulley
Original research: Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways (24 March, 2021)
Denise Cecil, Kyong Hwa Park, Benjamin Curtis, Lauren Corulli, Mary (Nora) Disis
Original research: MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination (23 March, 2021)
Xiaofang Wu, Marie Nelson, Mousumi Basu, Priya Srinivasan, Christopher Lazarski, Peng Zhang, Pan Zheng, Anthony David Sandler
Original research: Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages (22 March, 2021)
Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Ann-Lii Cheng, Muh-Hwa Yang, Chiun Hsu
Original research: Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial (19 March, 2021)
Kuimin Mei, Shukui Qin, Zhendong Chen, Ying Liu, Linna Wang, Jianjun Zou
Original research:
Human CD141⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
(18 March, 2021)
Yoke Seng Lee, Liam J O'Brien, Carina M Walpole, Frances E Pearson, Ingrid M Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J Radford
Original research: Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel (18 March, 2021)
David Gandara, Martin Reck, Denis Moro-Sibilot, Julien Mazieres, Shirish Gadgeel, Stefanie Morris, Andres Cardona, Diana Mendus, Marcus Ballinger, Achim Rittmeyer, Solange Peters
Original research: Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (18 March, 2021)
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, Delvys Rodríguez-Abreu, Jorge Alatorre-Alexander, Hans J M Smit, Jinming Yu, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Andres Cardona, Pablo D Perez-Moreno, Tom Newsom-Davis
Original research:
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2⁺ breast cancer stem-like cells
(15 March, 2021)
Stanley Ly, Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Debasish Tripathy, Aysegul A Sahin, Michael Andreeff, Venkata Lokesh Battula
Original research: Host response to immune checkpoint inhibitors contributes to tumor aggressiveness (11 March, 2021)
Irina Khononov, Eyal Jacob, Ella Fremder, Nili Dahan, Michal Harel, Ziv Raviv, Boris Krastev, Yuval Shaked
Original research: Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer (9 March, 2021)
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T Estrem, Karim A Benhadji, Mark C Lanasa, Emin Avsar, Susan C Guba, Rocio Garcia-Carbonero
Original research: Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma (9 March, 2021)
Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta Pal
Original research: Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy (9 March, 2021)
Veronica Olivo Pimentel, Damiënne Marcus, Alexander MA van der Wiel, Natasja G Lieuwes, Rianne Biemans, Relinde IY Lieverse, Dario Neri, Jan Theys, Ala Yaromina, Ludwig J Dubois, Philippe Lambin
Original research: Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer (4 March, 2021)
Ravi A Madan, Fatima Karzai, Renee N Donahue, Munjid Al-Harthy, Marijo Bilusic, Inger I Rosner, Harpreet Singh, Philip M Arlen, Marc R Theoret, Jennifer L Marté, Lisa Cordes, Anna Couvillon, Amy Hankin, Moniquea Williams, Helen Owens, Sarah E Lochrin, Cindy H Chau, Seth Steinberg, William Douglas Figg, William Dahut, Jeffrey Schlom, James L Gulley
Original research: Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (3 March, 2021)
Petra Ross-Macdonald, Alice M Walsh, Scott D Chasalow, Ron Ammar, Simon Papillon-Cavanagh, Peter M Szabo, Toni K Choueiri, Mario Sznol, Megan Wind-Rotolo
Original research: SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation (3 March, 2021)
Esther Redin, Irati Garmendia, Teresa Lozano, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Carlos E De Andrea, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Ana Remirez, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Ruben Pio, Juan Lasarte, Jackeline Agorreta, Luis M Montuenga, Alfonso Calvo
Original research: Electrocardiographic features of immune checkpoint inhibitor associated myocarditis (2 March, 2021)
Daniel A Zlotoff, Malek Z O Hassan, Amna Zafar, Raza M Alvi, Magid Awadalla, Syed S Mahmood, Lili Zhang, Carol L Chen, Stephane Ederhy, Ana Barac, Dahlia Banerji, Maeve Jones-O'Connor, Sean P Murphy, Merna Armanious, Brian J Forrestal, Michael C Kirchberger, Otavio R Coelho-Filho, Muhammad A Rizvi, Gagan Sahni, Anant Mandawat, Carlo G Tocchetti, Sarah Hartmann, Hannah K Gilman, Eduardo Zatarain-Nicolás, Michael Mahmoudi, Dipti Gupta, Ryan Sullivan, Sarju Ganatra, Eric H Yang, Lucie M Heinzerling, Franck Thuny, Leyre Zubiri, Kerry L Reynolds, Justine V Cohen, Alexander R Lyon, John Groarke, Paaladinesh Thavendiranathan, Anju Nohria, Michael G Fradley, Tomas G Neilan
Original research: Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study (2 March, 2021)
Niannian Ji, Neelam Mukherjee, Ryan M Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Tyler J Curiel, Robert S Svatek

Immune cell therapies and immune cell engineering

Original research: Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy (25 March, 2021)
Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger
Original research:
CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
(19 March, 2021)
Xuan Guo, Tanel Mahlakõiv, Qian Ye, Srinivas Somanchi, Shuyang He, Hemlata Rana, Andrea DiFiglia, Joseph Gleason, William van der Touw, Robert Hariri, Xiaokui Zhang
Original research: First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G (18 March, 2021)
François Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Marie Certoux, Philippe Souque, Francine Garnache, Olivier Adotevi, Pierre Langlade-Demoyen, Maria Loustau, Julien Caumartin
Original research: Designed improvement to T-cell immunotherapy by multidimensional single cell profiling (15 March, 2021)
Irfan N Bandey, Jay R T Adolacion, Gabrielle Romain, Melisa Martinez Paniagua, Xingyue An, Arash Saeedi, Ivan Liadi, Zheng You, Rasindu B Rajanayake, Patrick Hwu, Harjeet Singh, Laurence JN Cooper, Navin Varadarajan
Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model (11 March, 2021)
Tereza Andreou, Jennifer Williams, Rebecca J Brownlie, Robert J Salmond, Erica Watson, Gary Shaw, Alan Melcher, Heiko Wurdak, Susan C Short, Mihaela Lorger

Immunotherapy biomarkers

Original research: Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer (29 March, 2021)
Qiaoqi Sui, Dingxin Liu, Wu Jiang, Jinghua Tang, Lingheng Kong, Kai Han, Leen Liao, Yuan Li, Qingjian Ou, Binyi Xiao, Guochen Liu, Yihong Ling, Jiewei Chen, Zexian Liu, Zhixiang Zuo, Zhizhong Pan, Penghui Zhou, Jian Zheng, Pei-Rong Ding
Original research: High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer (25 March, 2021)
Yacine Bareche, Sandra Pommey, Mayra Carneiro, Laurence Buisseret, Isabelle Cousineau, Pamela Thebault, Pavel Chrobak, Laudine Communal, David Allard, Simon C Robson, Anne-Marie Mes-Masson, Diane Provencher, Rejean Lapointe, John Stagg
Original research: Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) (25 March, 2021)
Biagio Ricciuti, Greg Jones, Mariano Severgnini, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Tim Forshew, Christine Lydon, Mizuki Nishino, Michael Cheng, Mark Awad
Original research: Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients (24 March, 2021)
Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, Erwin Tomasich, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Wolfgang Lamm, Iris M Noebauer-Huhmann, Julia Furtner, Leonhard Müllauer, Gabriele Amann, Sebastian Bauer, Hans-Ulrich Schildhaus, Matthias Preusser, Gerwin Heller, Thomas Brodowicz
Original research: Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer (23 March, 2021)
Colt Egelston, Weihua Guo, Susan Yost, Jin Sun Lee, David Rose, Christian Avalos, Jian Ye, Paul Frankel, Daniel Schmolze, James Waisman, Peter Lee, Yuan Yuan
Original research: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score (22 March, 2021)
Gino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C T Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Andrea Marrari, M Carmen Carmona-García, Neha Chopra, Carlo Alberto Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia Andrea Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Ariadna Roqué, Alvin J X Lee, Tom Newsom-Davis, David García-Illescas, Roxana Reyes, Yien Ning Sophia Wong, Daniela Ferrante, Lorenza Scotti, Javier Marco-Hernández, Isabel Ruiz-Camps, Andrea Patriarca, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Armando Santoro, Aleix Prat, Alessandra Gennari, Mieke Van Hemelrijck, Josep Tabernero, Nikolaos Diamantis, David J Pinato
Original research: Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma (18 March, 2021)
Yuxiang Ma, Xi Chen, Ao Wang, Hongyun Zhao, Qingguang Lin, Hua Bao, Yang Zhang, Shaodong Hong, Wanxiangfu Tang, Yan Huang, Yunpeng Yang, Xue Wu, Yang Shao, Wenfeng Fang, Li Zhang
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape (18 March, 2021)
Matteo Caforio, Cristina Sorino, Ignazio Caruana, Gerrit Weber, Antonio Camera, Loredana Cifaldi, Biagio De Angelis, Francesca Del Bufalo, Alessia Vitale, Bianca Maria Goffredo, Rita De Vito, Doriana Fruci, Concetta Quintarelli, Maurizio Fanciulli, Franco Locatelli, Valentina Folgiero
Original research: Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC (18 March, 2021)
Shanying Gui, W Quinn O'Neill, Theodoros N Teknos, Quintin Pan
Original research: Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer (10 March, 2021)
Incheol Seo, Hye Won Lee, Sang Jun Byun, Jee Young Park, Hyeonji Min, Sung Hwan Lee, Ju-Seog Lee, Shin Kim, Sung Uk Bae
Original research: Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer (7 March, 2021)
Anna Wilkins, Elisa Fontana, Gift Nyamundanda, Chanthirika Ragulan, Yatish Patil, David Mansfield, Jennifer Kingston, Fiona Errington-Mais, Daniel Bottomley, Katharina von Loga, Hannah Bye, Paul Carter, Emma Tinkler-Hundal, Arish Noshirwani, Jessica Downs, Magnus Dillon, Sandra Demaria, David Sebag-Montefiore, Kevin Harrington, Nick West, Alan Melcher, Anguraj Sadanandam
Original research:
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
(2 March, 2021)
Landon C Brown, Matthew D Tucker, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang, Michael R Harrison, Daniel J George, Ajjai Alva, Emmanuel S Antonarakis, Andrew J Armstrong

Oncolytic and local immunotherapy

Original research: Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma (30 March, 2021)
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J Sacco, Kevin S Gorski, Abraham Anderson, Cheryl A Pickett, Kate Liu, Helen Gogas
Original research: Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche (19 March, 2021)
Louise M E Müller, Gemma Migneco, Gina B Scott, Jenny Down, Sancha King, Basem Askar, Victoria Jennings, Babatunde Oyajobi, Karen Scott, Emma West, Christy Ralph, Adel Samson, Elizabeth J Ilett, Munitta Muthana, Matt Coffey, Alan Melcher, Christopher Parrish, Gordon Cook, Michelle Lawson, Fiona Errington-Mais
Original research:
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A⁺CD141⁺ cDC1 and CD14⁺ antigen-presenting cell recruitment
(18 March, 2021)
Bas D Koster, Marta López González, Mari FCM van den Hout, Annelies W Turksma, Berbel JR Sluijter, Barbara G Molenkamp, Paul AM van Leeuwen, Saskia Vosslamber, Rik J Scheper, Alfons JM van den Eertwegh, M Petrousjka van den Tol, Ekaterina J Jordanova, Tanja D de Gruijl
Original research: Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma (18 March, 2021)
Alvaro Morales-Molina, Stefano Gambera, Angela Leo, Javier García-Castro
Original research: Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis (15 March, 2021)
Simon Gebremeskel, Adam Nelson, Brynn Walker, Tora Oliphant, Lynnea Lobert, Douglas Mahoney, Brent Johnston

Position article and guidelines

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) (29 March, 2021)
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, Eva Muñoz-Couselo, Carolina Ortiz, Roger Paredes, Daniel Podzamczer, Jose Luis Manzano, Jose Molto, Boris Revollo, Cristina Carrera, Lourdes Mateu, Sara Fancelli, Enrique Espinosa, Bonaventura Clotet, Javier Martinez-Picado, Pablo Cerezuela, Ainara Soria, Ivan Marquez-Rodas, Mario Mandala, Alfonso Berrocal

Review

Severity of COVID-19 in patients with lung cancer: evidence and challenges (18 March, 2021)
Antonio Passaro, Christine Bestvina, Maria Velez Velez, Marina Chiara Garassino, Edward Garon, Solange Peters
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic (11 March, 2021)
Renee N Donahue, Jennifer L Marté, Meghali Goswami, Nicole J Toney, Yo-Ting Tsai, James L Gulley, Jeffrey Schlom
Considerations for treatment duration in responders to immune checkpoint inhibitors (2 March, 2021)
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, Sabina Kaczanowska, Rania H Younis, Dipti Thakkar, Jiajia Zhang, Todd Bartkowiak, Rachel Howard, Kristin G Anderson, Daniel Olson, Abdul Rafeh Naqash, Ravi B Patel, Esha Sachdev, Maria E Rodriguez-Ruiz, Michal Sheffer, Sarah Church, Christopher Fuhrman, Abigail Overacre-Delgoffe, Rosa Nguyen, Vaia Florou, Jessica E Thaxton, David H Aggen, Jennifer L Guerriero

Main menu

Table of contents

March 2021 - Volume 9 - 3

Editorial

Case report

Commentary

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

March 2021 - Volume 9 - 3

Editorial

Case report

Commentary

Basic tumor immunology

Clinical/translational cancer immunotherapy

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction